Successful Management of Clozapine-induced Akathisia with Gabapentin Enacarbil: A Case Report
Clinical Psychopharmacology and Neuroscience
;
: 346-348, 2018.
Artículo
en Inglés
| WPRIM
| ID: wpr-716365
ABSTRACT
The management of clozapine (CLZ)-induced adverse events affects patient prognoses. Akathisia is a relatively rare adverse event related to CLZ administration and thus the management of this syndrome is not well established. Here, we report a case of treatment-resistant schizophrenia wherein CLZ-induced akathisia was successfully managed with gabapentin enacarbil (GE). The patient was a 39-year-old woman who had been treated with atypical antipsychotics other than CLZ for three years with poor tolerability. Initiation of CLZ (400 mg/day) attenuated her psychotic symptoms, but was followed by moderate akathisia. Neither benzodiazepines nor biperiden improved the akathisia; however, akathisia was finally diminished with co-administration of GE. GE facilitated a dosage increase in CLZ (450 mg/day) for the improved management of pyschotic symptoms, and thus indirectly contributed to treatment of the patient’s schizophrenia. We suggest that GE is a useful candidate for the management of CLZ-induced akathisia. The improved management of treatment-induced akathisia and other adverse events can extend the potential application of CLZ for treatment-resistant schizophrenia.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Pronóstico
/
Agitación Psicomotora
/
Síndrome de las Piernas Inquietas
/
Esquizofrenia
/
Antipsicóticos
/
Benzodiazepinas
/
Biperideno
/
Clozapina
Tipo de estudio:
Estudio pronóstico
Límite:
Adulto
/
Femenino
/
Humanos
Idioma:
Inglés
Revista:
Clinical Psychopharmacology and Neuroscience
Año:
2018
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS